Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2022-10-11 AGM Information
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: Raises 25 MNOK in new secured convertible loan and calls for extraordinary general meeting
AGM Information Classification · 98% confidence The document is explicitly titled "Notice of an extraordinary general meeting of SoftOx Solutions AS". It details the date, time, location, and the specific agenda items to be voted upon at this meeting, including a proposal for issuing a convertible loan. The document also includes attachments for attendance registration and proxy forms, which are characteristic of meeting notices. This directly aligns with the definition of an Annual General Meeting (AGM) related material, specifically the notice calling the meeting. Since the definition for AGM-R covers "Presentations and materials shared during the Annual General Meeting (AGM)", and this is the notice for an Extraordinary General Meeting (EGM), which functions similarly to an AGM in terms of shareholder voting and material distribution, AGM-R is the most appropriate classification, as there is no specific EGM code, and it is a core meeting document.
2022-10-11 Norwegian
SoftOx Solutions AS: Raises 25 MNOK in new secured convertible loan and calls for extraordinary general meeting
Capital/Financing Update Classification · 98% confidence The document explicitly announces two main actions: 1) Raising NOK 25 MNOK in a new secured convertible loan (a financing activity) and 2) Calling for an extraordinary general meeting (EGM) to approve this loan. The core subject is the capital raising/financing structure (convertible loan details, interest rate, conversion price, refinancing). This strongly aligns with the 'Capital/Financing Update' definition (CAP). Although it also calls for an EGM, the primary driver and bulk of the text detail the financial transaction itself. Since the financing aspect is dominant, CAP is the most appropriate primary classification.
2022-10-11 English
SoftOx Solutions AS: Received final assessment draft from the Swedish Chemicals Agency on disinfection products
Regulatory Filings Classification · 95% confidence The document is a short press release from SoftOx Solutions AS announcing that they have received a final product assessment draft from the Swedish Chemicals Agency regarding their disinfection products. It discusses the next steps (final decision, mutual recognition in the EU) and future business plans (distributor talks). This is not a full financial report (10-K, IR, ER), nor is it a specific regulatory filing like a Director's Dealing or Capital Change. Since it is a general announcement regarding regulatory progress and business updates that doesn't fit the specific categories like M&A (TAR) or Dividend (DIV), the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory update/announcement.
2022-10-04 English
SOFTOX SOLUTIONS AS: POSITIVE TOP LINE PHASE 1 RESULTS FOR SOFTOX BIOFILM ERADICATOR - UPDATE ON THE COMPANY’S FINANCIAL SITUATION
Regulatory Filings Classification · 94% confidence The document is a press release from SoftOx Solutions AS announcing positive top-line Phase 1 clinical results for their Biofilm Eradicator (SBE) and providing an update on the company's financial situation, including plans for cost reduction and potential fundraising (rights issue). It contains clinical data summaries, management commentary, and financial outlook. This structure strongly suggests an Earnings Release (ER) or a comprehensive announcement that covers both operational/clinical updates and financial status, which often overlaps with an Earnings Release or a comprehensive Interim Report (IR) if it were quarterly. However, since it is a specific announcement of clinical trial results combined with a financial update, and it is not explicitly labeled as a quarterly report (IR) or a full annual report (10-K), the most fitting category for a major operational/clinical update accompanied by a financial status review is the Earnings Release (ER), as these often include operational highlights alongside financial performance context. Given the focus on clinical proof-of-concept and the financial need, it functions as a major operational update announcement. Reviewing the definitions: - ER (Earnings Release): Initial announcement of periodical financial results (key highlights only). This document contains key financial highlights and operational milestones. - IR (Interim Report): Comprehensive financial report for a shorter period. This is not explicitly labeled as a quarterly/interim financial report. - LTR (Legal Proceedings Report): Not primarily about legal proceedings. - CAP (Capital/Financing Update): It discusses financing needs, but the primary driver is the clinical result announcement. Since it combines significant clinical progress (proof-of-concept) with a financial update (cash position, funding needs), it aligns best with the function of an Earnings Release (ER) which typically summarizes the period's key achievements and financial standing, even if the primary news is clinical. The document ends by stating the information is disclosed pursuant to MAR article 17, typical for regulatory announcements, but the content is substantive enough to be classified beyond a simple RNS.
2022-10-04 English
SoftOx Solutions AS: Announces the end of the SBE Phase 1 clinical study for treatment of chronic wounds
Regulatory Filings Classification · 90% confidence The document is a press release announcing the completion of a Phase 1 clinical study for a product (SBE-01) and mentions that top-line results will be announced in Q4 2022. It details the study's purpose, funding sources (NMRC), and next steps (planning Phase 2). This type of announcement, which communicates a specific operational milestone (end of a study phase) rather than comprehensive financial results (ER/IR) or a formal regulatory filing, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. Given the nature of the announcement—a specific operational update that is not a standard financial report or a formal regulatory form like 10-K or DEF 14A—RNS serves as the most appropriate general category for non-standard corporate news releases. Since the document length is moderate (4223 chars) and it is a direct announcement, it is not an RPA (which usually announces the publication of another document).
2022-09-05 English
SoftOx Solutions AS: Strengthens its leadership team
Board/Management Information Classification · 100% confidence The document is a press release dated September 1, 2022, announcing the appointment of new personnel (Senior Advisor and Project Director) and an interim CEO change within a subsidiary. This type of announcement, detailing changes in the company's senior leadership or board of directors, directly corresponds to the definition of 'Board/Management Information'. The document length (4038 characters) is typical for a press release, not a comprehensive regulatory filing like a 10-K or IR. Therefore, the appropriate code is MANG.
2022-09-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.